Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

A game changing technology to revolutionise donor organ preservation and enlarge the pool of organs for transplantation

Project description

New tech for donor organ preservation

Thousands of people in Europe are on waiting lists for organ transplants. Unfortunately, current transplantations cover less than 20 % of the actual need. The goal is to ensure all patients on transplant waiting lists receive the needed organs. The EIC-funded Vivalyx project is developing a new technology called Omnisol. This is a fully synthetic blood substitute had outperformed blood in pre-clinical trials. The project aims to bring this technology to the clinical stage and lastly to the market, making this essential organ preservation technique truly scalable for the first time. This will provide significant benefits for patients awaiting transplants.

Objective

There are over 150,000 people on waiting lists for organ transplantation in Europe and the US today. Current transplantations cover less than 20% of the actual need, estimated at 1M organs by the WHO, due to the shortage of available transplantable organs. Predominantly used organ preservation methods fail at extending the pool of available organs. Perfusion at body temperature is the optimal organ preservation technology and it can expand the donor organ pool as it enables viability assessment and revitalisation before transplant. However, it is still underutilized in the clinical practice due to the requirement of blood, high costs and complexity of use, which makes it hardly scalable. Vivalyx has invented a game changing technology that unlocks the benefits of warm perfusion. This is Omnisol, a fully synthetic blood substitute solution that outperforms blood 3x in terms of organ viability and function during preservation. Vivalyx technology enables 3-4x organ pool expansion due to the organ resuscitation capabilities. Vivalyx was founded in 2022 by a group of scientists and medtech entrepreneurs with the vision of enabling all patients on transplant waiting lists to receive the organ they need. Through the EIC project Vivalyx will bring body temperature perfusion to the market, making this key technique of organ preservation scalable for the first time, creating tangible benefits for patients on transplant waiting lists.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC-ACC - HORIZON EIC Accelerator

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2024-ACCELERATOR-02

See all projects funded under this call

Coordinator

VIVALYX GMBH
Net EU contribution
€ 2 484 382,00
Address
GOTTFRIED-HAGEN-STRASSE 60-62
51105 Koln
Germany
SME
Yes
Region
Nordrhein-Westfalen Köln Köln, Kreisfreie Stadt
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
No data